Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT6OEDT)

• DTT Name: Cannabinoid receptor 1 (CB1) DTT Info
• Gene Name: CNR1

Molecule-Related Drug & Molecule List

4 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[1]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[2]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[3]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[4]

10 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tebipenem	DMVSX6O	Urinary tract infection	GC08	Phase 3	[5]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[6]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[7]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[8]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[9]
SR-147778	DMNAECP	Obesity	5B81	Phase 2	[10]
GFB-024	DM0L401	Diabetic nephropathy	GB61.Z	Phase 1	[11]
TM38837	DMCFGD4	Metabolic disorder	5C50-5D2Z	Phase 1	[12]
V-24343	DMJSX9N	Type-2 diabetes	5A11	Phase 1	[13]
ZY01	DMSLPTO	Diabetic complication	5A2Y	Phase 1	[14]

162 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1,2,3-triazole derivative 1	DMKHF39	Obesity	5B81	Patented	[15]
1,2,3-triazole derivative 2	DMFR23C	Obesity	5B81	Patented	[15]
1,2,4,5-tetra-substituted imidazole derivative 1	DMLAYG7	Obesity	5B81	Patented	[15]
1,2,4,5-tetra-substituted imidazole derivative 2	DMMCYI5	Obesity	5B81	Patented	[15]
1,2,4-tri-substituted imidazoline derivative 1	DMMNVZ5	Obesity	5B81	Patented	[15]
1,2,4-triazole derivative 1	DME8MN1	Obesity	5B81	Patented	[15]
1,2,4-triazole derivative 2	DM91Z8B	Obesity	5B81	Patented	[15]
1,5-diphenylpyrrolidin-2-one derivative 1	DMZY3HC	Obesity	5B81	Patented	[15]
1,5-diphenylpyrrolidin-2-one derivative 2	DMBR2Y9	Obesity	5B81	Patented	[15]
2-cycloalkyl resorcinol cannabinoid ligand derivative 1	DMLXQET	N. A.	N. A.	Patented	[16]
2-cycloalkyl resorcinol cannabinoid ligand derivative 2	DMB65TO	N. A.	N. A.	Patented	[16]
4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide derivative 1	DMNTOZV	Obesity	5B81	Patented	[15]
Amide derivative 1	DMO64LA	Obesity	5B81	Patented	[15]
Aminoazetidine derivative 1	DMNI0M1	Obesity	5B81	Patented	[15]
Aminoazetidine derivative 2	DMHSNA5	Obesity	5B81	Patented	[15]
Aminoazetidine derivative 3	DMOQHA9	Obesity	5B81	Patented	[15]
Aminoazetidine derivative 4	DM50E4Y	Obesity	5B81	Patented	[15]
Aminoazetidine derivative 5	DMYPD4Z	Obesity	5B81	Patented	[15]
Aminoazetidine derivative 7	DM3LNQG	Obesity	5B81	Patented	[15]
Aminoazetidine derivative 8	DMLOIHD	Obesity	5B81	Patented	[15]
Aminoazetidine derivative 9	DMUASHT	Obesity	5B81	Patented	[15]
Azetidine derivative 1	DMXEFUD	Obesity	5B81	Patented	[15]
Azetidine derivative 3	DMIKSVG	Obesity	5B81	Patented	[15]
Azetidine derivative 4	DMXL2V9	Obesity	5B81	Patented	[15]
Azetidine-1-carboxamide derivative 1	DMZX8Y0	Obesity	5B81	Patented	[15]
Azetidine-1-carboxamide derivative 2	DMONQ4L	Obesity	5B81	Patented	[15]
Azetidine-1-carboxamide derivative 3	DM2UGK3	Obesity	5B81	Patented	[15]
Benzimidazole derivative 1	DML8W16	Obesity	5B81	Patented	[15]
Benzimidazole derivative 2	DM4ZUDY	Obesity	5B81	Patented	[15]
Carbazole-3-carboxamide analog 1	DM3B5RS	N. A.	N. A.	Patented	[16]
Carboxamide derivative 1	DM5GEBH	Obesity	5B81	Patented	[15]
Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1	DMMX1ZE	N. A.	N. A.	Patented	[16]
Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2	DM6GTDM	N. A.	N. A.	Patented	[16]
Diaryl morpholine derivative 1	DMIQOY7	Obesity	5B81	Patented	[15]
Diaryl piperazine derivative 1	DMERQ7V	Obesity	5B81	Patented	[15]
Diaryl piperazine derivative 2	DMDOB20	Obesity	5B81	Patented	[15]
Diphenyl purine derivative 1	DM2DYMS	Obesity	5B81	Patented	[15]
Diphenyl purine derivative 2	DMG8MCJ	Obesity	5B81	Patented	[15]
Diphenyl purine derivative 3	DMY5CFW	Obesity	5B81	Patented	[15]
Diphenyl purine derivative 4	DMP3JF4	Obesity	5B81	Patented	[15]
Diphenyl purine derivative 5	DMC2T4H	Obesity	5B81	Patented	[15]
Furopyridine derivative 1	DM2QXVW	Obesity	5B81	Patented	[15]
Furopyridine derivative 2	DMEU3J9	Obesity	5B81	Patented	[15]
Heterocyclic-substituted 3-alkyl azetidine derivative 1	DMJEX3D	Obesity	5B81	Patented	[15]
Heterocyclic-substituted 3-alkyl azetidine derivative 2	DMEX7PV	Obesity	5B81	Patented	[15]
Heterocyclic-substituted 3-alkyl azetidine derivative 3	DMO1Y30	Obesity	5B81	Patented	[15]
Hydrazide derivative 1	DMUA740	Obesity	5B81	Patented	[15]
Imidazole derivative 1	DM14KHX	Obesity	5B81	Patented	[15]
Imidazole derivative 2	DM8GCVO	Obesity	5B81	Patented	[15]
Imidazole derivative 3	DMV1ER2	Obesity	5B81	Patented	[15]
Imidazole derivative 4	DMPGMX2	Obesity	5B81	Patented	[15]
Imidazole derivative 5	DMVSXUM	Obesity	5B81	Patented	[15]
Imidazole derivative 6	DMOXHZJ	Obesity	5B81	Patented	[15]
Imidazole derivative 7	DMLPQ7E	Obesity	5B81	Patented	[15]
Imidazolidine-2,4-dione derivative 1	DMUFSQ2	Obesity	5B81	Patented	[15]
Imidazolidine-2,4-dione derivative 2	DMVMD2O	Obesity	5B81	Patented	[15]
N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2	DMD4CU5	Osteoporosis	FB83.0	Patented	[16]
N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3	DMM78VS	Osteoporosis	FB83.0	Patented	[16]
N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1	DM6TYM0	Obesity	5B81	Patented	[15]
N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 2	DM2MPN0	Obesity	5B81	Patented	[15]
N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 1	DM9A8L5	Obesity	5B81	Patented	[15]
N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 2	DM8T2LV	Obesity	5B81	Patented	[15]
N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 3	DMEH0RC	Obesity	5B81	Patented	[15]
Phytocannabinoid/aminoalkylindole derivative 1	DMM9F8D	N. A.	N. A.	Patented	[16]
Phytocannabinoid/aminoalkylindole derivative 2	DMOXJ7Q	N. A.	N. A.	Patented	[16]
Piperazine derivative 1	DMJ7F1Q	Obesity	5B81	Patented	[15]
Piperazine derivative 2	DM4JZ2T	Obesity	5B81	Patented	[15]
PMID26161824-Compound-68	DMF9C4I	Obesity	5B81	Patented	[15]
PMID26161824-Compound-69	DMKOSN5	Obesity	5B81	Patented	[15]
PMID27215781-Compound-1	DM84RES	N. A.	N. A.	Patented	[16]
PMID27215781-Compound-2	DMBOX0K	N. A.	N. A.	Patented	[16]
PMID27215781-Compound-37	DM0L68P	Prostate cancer	2C82.0	Patented	[16]
Purine derivative 1	DMB65Z4	Obesity	5B81	Patented	[15]
Purine derivative 2	DMNRG0P	Obesity	5B81	Patented	[15]
Purine derivative 3	DMPI2S9	Obesity	5B81	Patented	[15]
Pyrano[2,3-b]pyridine derivative 1	DMMVG2O	Obesity	5B81	Patented	[15]
Pyrano[2,3-b]pyridine derivative 2	DMOJ8P1	Obesity	5B81	Patented	[15]
Pyrazole derivative 1	DM3R9PL	Obesity	5B81	Patented	[15]
Pyrazole derivative 11	DMH7PGU	Obesity	5B81	Patented	[15]
Pyrazole derivative 12	DM7LFNG	Obesity	5B81	Patented	[15]
Pyrazole derivative 13	DM5S3L0	Obesity	5B81	Patented	[15]
Pyrazole derivative 14	DMEDXW9	Obesity	5B81	Patented	[15]
Pyrazole derivative 15	DMJCX8M	Obesity	5B81	Patented	[15]
Pyrazole derivative 16	DM5A8F3	Obesity	5B81	Patented	[15]
Pyrazole derivative 17	DM7F9V4	Obesity	5B81	Patented	[15]
Pyrazole derivative 18	DMVZ8KD	Obesity	5B81	Patented	[15]
Pyrazole derivative 19	DMM7OR3	Obesity	5B81	Patented	[15]
Pyrazole derivative 2	DMIS97T	Obesity	5B81	Patented	[15]
Pyrazole derivative 20	DM2HO1S	Obesity	5B81	Patented	[15]
Pyrazole derivative 21	DMUPNHA	Obesity	5B81	Patented	[15]
Pyrazole derivative 22	DMCS08K	Obesity	5B81	Patented	[15]
Pyrazole derivative 23	DMH2LFS	Obesity	5B81	Patented	[15]
Pyrazole derivative 24	DMVX2D0	Obesity	5B81	Patented	[15]
Pyrazole derivative 25	DMM2RYG	Obesity	5B81	Patented	[15]
Pyrazole derivative 26	DMX92ZK	Obesity	5B81	Patented	[15]
Pyrazole derivative 27	DMDB5FH	Obesity	5B81	Patented	[15]
Pyrazole derivative 28	DMYEFW1	Obesity	5B81	Patented	[15]
Pyrazole derivative 29	DM7DTYS	Obesity	5B81	Patented	[15]
Pyrazole derivative 3	DMX2NQW	Obesity	5B81	Patented	[15]
Pyrazole derivative 30	DMT1DJP	Obesity	5B81	Patented	[15]
Pyrazole derivative 31	DMDTQCG	Obesity	5B81	Patented	[15]
Pyrazole derivative 32	DMU59IJ	Obesity	5B81	Patented	[15]
Pyrazole derivative 33	DMUNLK8	Obesity	5B81	Patented	[15]
Pyrazole derivative 34	DMRH2EJ	Obesity	5B81	Patented	[15]
Pyrazole derivative 35	DM6KROX	Obesity	5B81	Patented	[15]
Pyrazole derivative 36	DMSDVI1	Obesity	5B81	Patented	[15]
Pyrazole derivative 37	DMZJ5FN	Obesity	5B81	Patented	[15]
Pyrazole derivative 38	DMPVDSC	Obesity	5B81	Patented	[15]
Pyrazole derivative 39	DMMGWKE	Obesity	5B81	Patented	[15]
Pyrazole derivative 4	DM2DK1E	Obesity	5B81	Patented	[15]
Pyrazole derivative 40	DM7CMV6	Obesity	5B81	Patented	[15]
Pyrazole derivative 5	DMDGSKH	Obesity	5B81	Patented	[15]
Pyrazole derivative 53	DMMIOZ5	Obesity	5B81	Patented	[15]
Pyrazole derivative 54	DM9PNTF	Obesity	5B81	Patented	[15]
Pyrazole derivative 57	DMZ3J78	Obesity	5B81	Patented	[15]
Pyrazole derivative 58	DMZIOW0	Obesity	5B81	Patented	[15]
Pyrazole derivative 59	DMXZC8K	Obesity	5B81	Patented	[15]
Pyrazole derivative 6	DMIDN6T	Obesity	5B81	Patented	[15]
Pyrazole derivative 60	DMQ08BM	Obesity	5B81	Patented	[15]
Pyrazole derivative 7	DMYKU0T	Obesity	5B81	Patented	[15]
Pyrazole derivative 8	DMMRTAL	Obesity	5B81	Patented	[15]
Pyrazoline derivative 1	DMGS2ET	Obesity	5B81	Patented	[15]
Pyrazoline derivative 10	DMCZORA	Obesity	5B81	Patented	[15]
Pyrazoline derivative 11	DMAB3YG	Obesity	5B81	Patented	[15]
Pyrazoline derivative 2	DMOA8E4	Obesity	5B81	Patented	[15]
Pyrazoline derivative 3	DMGH0LQ	Obesity	5B81	Patented	[15]
Pyrazoline derivative 4	DMRT7I8	Obesity	5B81	Patented	[15]
Pyrazoline derivative 5	DMEGS9U	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 1	DM0FPMV	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 10	DM07GEK	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 11	DM0O4WR	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 12	DMMLDUI	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 13	DMR5O7T	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 2	DMO3MJ7	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 3	DMHTV47	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 4	DMCAVF0	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 5	DM3UBG2	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 6	DM5E1KS	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 7	DMFUSPR	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 8	DMTQNYZ	Obesity	5B81	Patented	[15]
Pyrazolo[1,5-a]pyrimidine derivative 9	DMXAW2S	Obesity	5B81	Patented	[15]
Pyridotriazolopyrimidine derivative 1	DM71UYI	Obesity	5B81	Patented	[15]
Pyridotriazolopyrimidine derivative 2	DM0VOY9	Obesity	5B81	Patented	[15]
Pyridotriazolopyrimidine derivative 3	DMYVCTD	Obesity	5B81	Patented	[15]
Pyrido[2,3-d]pyrimidine derivative 1	DMHZLSO	Obesity	5B81	Patented	[15]
Pyrido[2,3-d]pyrimidine derivative 2	DMSM53I	Obesity	5B81	Patented	[15]
Pyrrole derivative 1	DM0RC1Z	Obesity	5B81	Patented	[15]
Pyrrole derivative 2	DMMNKFX	Obesity	5B81	Patented	[15]
Pyrrole derivative 3	DMFV64B	Obesity	5B81	Patented	[15]
Pyrrole derivative 4	DMQDL43	Obesity	5B81	Patented	[15]
Pyrrole derivative 5	DMJUMC6	Obesity	5B81	Patented	[15]
Pyrrole derivative 6	DM875RE	Obesity	5B81	Patented	[15]
Sulfonamide derivative 1	DMTX21L	Obesity	5B81	Patented	[15]
Sulfonylated piperazine derivative 1	DMCO8JD	Obesity	5B81	Patented	[15]
Sulfonylated piperazine derivative 2	DMZYPV3	Obesity	5B81	Patented	[15]
Sulfonylated piperazine derivative 3	DMOJAZ9	Obesity	5B81	Patented	[15]
Sulfonylated piperazine derivative 4	DMZW2XP	Obesity	5B81	Patented	[15]
Sulfonylated piperazine derivative 5	DM65NBS	Obesity	5B81	Patented	[15]
Tetra-hydro-1H-1,2,6-triazaazulene derivative 1	DMUXNKG	Obesity	5B81	Patented	[15]
Tetra-hydro-1H-1,2,6-triazaazulene derivative 2	DMVTZ6S	Obesity	5B81	Patented	[15]
Tricyclic phytocannabinoid derivative 1	DM94NZF	Neuropathic pain	8E43.0	Patented	[16]
Tricyclic phytocannabinoid derivative 2	DM7YVQL	Neuropathic pain	8E43.0	Patented	[16]

13 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CP-945598	DMOU173	Obesity	5B81	Discontinued in Phase 3	[17]
Taranabant	DM5G9W0	Obesity	5B81	Discontinued in Phase 3	[18]
AVE1625	DMXNK0J	Psychotic disorder	6A20-6A25	Discontinued in Phase 2	[19]
AZD2207	DM1TDWI	Diabetic complication	5A2Y	Discontinued in Phase 2	[7]
KDS-2000	DMX9M53	Postherpetic neuralgia	1E91.5	Discontinued in Phase 2	[20]
KN-38-7271	DMN4BIA	Ischemia	8B10-8B11	Discontinued in Phase 2	[21]
SLV319	DM0GKHX	Obesity	5B81	Discontinued in Phase 2	[22]
AZD1175	DM65MUI	Diabetic complication	5A2Y	Discontinued in Phase 1	[7]
AZD1704	DMVE4P3	Pain	MG30-MG3Z	Discontinued in Phase 1	[7]
CBD cannabis derivative	DM3G4JD	Schizophrenia	6A20	Discontinued in Phase 1	[23]
PF-514273	DMS7M0U	Obesity	5B81	Discontinued in Phase 1	[24]
TAK-937	DM13YN0	Cerebrovascular ischaemia	8B1Z	Discontinued in Phase 1	[25]
WIN-55212-2	DMACBIW	N. A.	N. A.	Terminated	[27]

2 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CB1 antagonist, Bayer	DM53JW0	Obesity	5B81	Preclinical	[5]
JD-5037	DMTGI64	Diabetic complication	5A2Y	Preclinical	[26]

182 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(1R,2R)-N-Arachidonoylcyclopropanolamide	DMYLPV1	Discovery agent	N.A.	Investigative	[28]
(1R,2S)-N-Arachidonoylcyclopropanolamide	DM39AFU	Discovery agent	N.A.	Investigative	[28]
(1R,2S)-N-Oleoylcyclopropanolamide	DMITW5P	Discovery agent	N.A.	Investigative	[28]
(1S,2S)-N-Arachidonoylcyclopropanolamide	DMKA0ON	Discovery agent	N.A.	Investigative	[28]
(1S,2S)-N-Oleoylcyclopropanolamide	DMIV2OY	Discovery agent	N.A.	Investigative	[28]
(2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	DMXPQU6	Discovery agent	N.A.	Investigative	[29]
(2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	DMX0YIV	Discovery agent	N.A.	Investigative	[29]
(2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	DMRCMIT	Discovery agent	N.A.	Investigative	[29]
(4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone	DM1XY7C	Discovery agent	N.A.	Investigative	[30]
(E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide	DM9WHD2	Discovery agent	N.A.	Investigative	[31]
(E)-N-(4-methoxyphenethyl)undec-2-enamide	DML6PJD	Discovery agent	N.A.	Investigative	[31]
(E)-N-(4-methoxyphenyl)undec-2-enamide	DM1PCEM	Discovery agent	N.A.	Investigative	[31]
1,3,5-triphenylimidazolidine-2,4-dione	DM7U6S0	Discovery agent	N.A.	Investigative	[32]
1,3,5-tris(4-chlorophenyl)imidazolidine-2,4-dione	DMDNM05	Discovery agent	N.A.	Investigative	[32]
1,4-dihydroindeno[1,2-c]-pyrazole	DMMGP9X	Discovery agent	N.A.	Investigative	[33]
1,5-bis(4-chlorophenyl)-1H-1,2,3-triazole	DMF0RXK	Discovery agent	N.A.	Investigative	[34]
1-(2-morpholinoethyl)-1H-indol-3-yl acetate	DMZF0D3	Discovery agent	N.A.	Investigative	[35]
1-(4-CHLOROPHENYL)-2-(2,4-DICHLOROPHENYL)-5-(METHYLSULFINYL)-N-(PIPERIDIN-1-YL)-1H-IMIDAZOLE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	DMV8C7I	Discovery agent	N.A.	Investigative	[36]
1-(bis(4-bromophenyl)methyl)-3-phenylurea	DMYO8D3	Discovery agent	N.A.	Investigative	[37]
1-(bis(4-chlorophenyl)methyl)-3-phenylurea	DMTVNO3	Discovery agent	N.A.	Investigative	[37]
1-[bis(4-bromophenyl)methyl]-3-phenylthiourea	DM13D4E	Discovery agent	N.A.	Investigative	[37]
1-[bis(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-	DMN2LHM	Discovery agent	N.A.	Investigative	[37]
1-[bis(4-chlorophenyl)methyl]-3-phenylthiourea	DMFMR2N	Discovery agent	N.A.	Investigative	[37]
1-[bis(4-iodophenyl)methyl]-3-(4-bromophenyl)urea	DMJT7VI	Discovery agent	N.A.	Investigative	[37]
2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol	DMTP3LD	Discovery agent	N.A.	Investigative	[38]
2-Benzylbenzo[f]chromen-3-one	DMM48L6	Discovery agent	N.A.	Investigative	[27]
3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol	DMJ7Y3H	Discovery agent	N.A.	Investigative	[38]
3,4-diarylpyrazoline derivative	DM8R03D	Discovery agent	N.A.	Investigative	[39]
3-Benzyl-5-isopropyl-8-methylchromen-2-one	DMKZDYP	Discovery agent	N.A.	Investigative	[27]
3-Benzyl-5-methoxy-7-methylchromen-2-one	DMF04YH	Discovery agent	N.A.	Investigative	[27]
3-Benzyl-5-methoxychromen-2-one	DMSIAMN	Discovery agent	N.A.	Investigative	[27]
4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol	DMQ6EBR	Discovery agent	N.A.	Investigative	[38]
4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol	DMV4QRF	Discovery agent	N.A.	Investigative	[38]
4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol	DM5BN41	Discovery agent	N.A.	Investigative	[38]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[40]
4-benzhydryl-N-butylpiperazine-1-carboxamide	DMVSNPB	Discovery agent	N.A.	Investigative	[30]
4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide	DMASO86	Discovery agent	N.A.	Investigative	[30]
4-cyanophenyl ethyl dodecylphosphonate	DMEP80Q	Discovery agent	N.A.	Investigative	[41]
5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol	DMS31H9	Discovery agent	N.A.	Investigative	[38]
5-Biphenyl-4-ylmethyl-2-isobutyl-2H-tetrazole	DMCPIK5	Discovery agent	N.A.	Investigative	[42]
5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one	DMW9D30	Discovery agent	N.A.	Investigative	[27]
6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	DM0C1FX	Discovery agent	N.A.	Investigative	[29]
6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	DM1N46J	Discovery agent	N.A.	Investigative	[29]
6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	DM5H4KE	Discovery agent	N.A.	Investigative	[29]
6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)	DMEJ83H	Ovarian cancer	2C73	Investigative	[29]
A-796260	DMHFPRJ	Pain	MG30-MG3Z	Investigative	[43]
ACEA	DMWX3HT	Discovery agent	N.A.	Investigative	[44]
AM-1241	DMFVGXW	Discovery agent	N.A.	Investigative	[43]
AM-1710	DMO7QUP	Discovery agent	N.A.	Investigative	[45]
AM-1714	DMW9ERM	Discovery agent	N.A.	Investigative	[45]
AM-1715	DMKJQZ4	Discovery agent	N.A.	Investigative	[45]
AM-281	DMOKN27	Discovery agent	N.A.	Investigative	[27]
AM-404	DMBK9PS	Discovery agent	N.A.	Investigative	[46]
AM-411	DMU3Y4J	Discovery agent	N.A.	Investigative	[47]
AM-4768	DMETXA8	Discovery agent	N.A.	Investigative	[45]
AM-630	DM7R605	Discovery agent	N.A.	Investigative	[48]
AM251	DMTAWHL	Discovery agent	N.A.	Investigative	[49]
Anandamide	DMCKH3P	Discovery agent	N.A.	Investigative	[50]
arachidonylcyclopropylamide	DMZM5KE	Discovery agent	N.A.	Investigative	[44]
AZ-599	DM1XE4F	Pain	MG30-MG3Z	Investigative	[51]
BMS-812204	DM1HBF5	Obesity	5B81	Investigative	[51]
cannabinol	DMM6A7P	Discovery agent	N.A.	Investigative	[52]
Chlorphrifos oxon	DMGBT68	Discovery agent	N.A.	Investigative	[41]
Cis-N-oleoylcyclopropanolamide	DM7TU1I	N. A.	N. A.	Investigative	[28]
CP-4497	DMTHVCA	Discovery agent	N.A.	Investigative	[53]
CXB-029	DMAPRDE	Central nervous system disease	8A04-8D87	Investigative	[51]
DELTA 8-TETRAHYDROCANNOBINOL	DM5ARHI	Discovery agent	N.A.	Investigative	[54]
Dibenzothiazepines	DMEDKA3	Drug abuse	6C4G.1Z	Investigative	[51]
Dodecane-1-sulfonyl fluoride	DME9CGK	Discovery agent	N.A.	Investigative	[41]
HU210	DM48F3D	Discovery agent	N.A.	Investigative	[55]
Isopropyl 4-nitrophenyl dodecylphosphonate	DM2VJF4	Discovery agent	N.A.	Investigative	[41]
Isopropyl dodecylfluorophosphonate	DML54EA	Discovery agent	N.A.	Investigative	[56]
JWH-120	DM7JQDS	Discovery agent	N.A.	Investigative	[57]
JWH-133	DM1DEYU	Discovery agent	N.A.	Investigative	[58]
JWH-145	DMZQ31O	Discovery agent	N.A.	Investigative	[59]
JWH-146	DMU7E6A	Discovery agent	N.A.	Investigative	[59]
JWH-147	DMEX9GV	Discovery agent	N.A.	Investigative	[59]
JWH-150	DM86OZD	Discovery agent	N.A.	Investigative	[59]
JWH-156	DMWGSQO	Discovery agent	N.A.	Investigative	[59]
JWH-229	DMMKYGP	Discovery agent	N.A.	Investigative	[57]
JWH-243	DMGD73A	Discovery agent	N.A.	Investigative	[59]
JWH-244	DMETAOU	Discovery agent	N.A.	Investigative	[59]
JWH-245	DMC5RZ9	Discovery agent	N.A.	Investigative	[59]
JWH-246	DMGTEYB	Discovery agent	N.A.	Investigative	[59]
JWH-268	DM07XBG	Discovery agent	N.A.	Investigative	[57]
JWH-292	DM5FAUY	Discovery agent	N.A.	Investigative	[59]
JWH-293	DMCK1XR	Discovery agent	N.A.	Investigative	[59]
JWH-297	DM4A761	Discovery agent	N.A.	Investigative	[60]
JWH-307	DM23RUZ	Discovery agent	N.A.	Investigative	[59]
JWH-308	DMV5ASE	Discovery agent	N.A.	Investigative	[59]
JWH-309	DMTV1B9	Discovery agent	N.A.	Investigative	[59]
JWH-324	DMJ2EI9	Discovery agent	N.A.	Investigative	[53]
JWH-325	DMHNTZ8	Discovery agent	N.A.	Investigative	[60]
JWH-337	DMK3DUZ	Discovery agent	N.A.	Investigative	[60]
JWH-342	DMTSZFB	Discovery agent	N.A.	Investigative	[60]
JWH-344	DM6VZ3T	Discovery agent	N.A.	Investigative	[60]
JWH-345	DML53SK	Discovery agent	N.A.	Investigative	[60]
JWH-346	DMHNILP	Discovery agent	N.A.	Investigative	[59]
JWH-347	DMK2NQ1	Discovery agent	N.A.	Investigative	[59]
JWH-348	DMQIVPK	Discovery agent	N.A.	Investigative	[59]
JWH-363	DMFLB1Z	Discovery agent	N.A.	Investigative	[59]
JWH-364	DMP6C4D	Discovery agent	N.A.	Investigative	[59]
JWH-365	DM2ZXBR	Discovery agent	N.A.	Investigative	[59]
JWH-366	DMSNLFJ	Discovery agent	N.A.	Investigative	[59]
JWH-367	DM7ZF2K	Discovery agent	N.A.	Investigative	[59]
JWH-368	DMK0FNX	Discovery agent	N.A.	Investigative	[59]
JWH-369	DMPDTWY	Discovery agent	N.A.	Investigative	[59]
JWH-370	DM6IG7P	Discovery agent	N.A.	Investigative	[59]
JWH-371	DME0URP	Discovery agent	N.A.	Investigative	[59]
JWH-372	DM9D3GM	Discovery agent	N.A.	Investigative	[59]
JWH-373	DMWP84R	Discovery agent	N.A.	Investigative	[59]
JWH-385	DMU1HA7	Discovery agent	N.A.	Investigative	[60]
JWH-392	DMMUBIF	Discovery agent	N.A.	Investigative	[60]
JWH-401	DMFL6B9	Discovery agent	N.A.	Investigative	[60]
JWH-402	DM8TQIF	Discovery agent	N.A.	Investigative	[60]
JWH-403	DMRG1VI	Discovery agent	N.A.	Investigative	[60]
JWH-404	DM3KWER	Discovery agent	N.A.	Investigative	[60]
JWH-405	DM57TN3	Discovery agent	N.A.	Investigative	[60]
JWH-406	DMNP7GD	Discovery agent	N.A.	Investigative	[60]
JWH-407	DMZQ0V9	Discovery agent	N.A.	Investigative	[60]
JWH-440	DM89602	Discovery agent	N.A.	Investigative	[53]
JWH-442	DMX6F1L	Discovery agent	N.A.	Investigative	[53]
KM-233	DMZSYKC	Discovery agent	N.A.	Investigative	[61]
KM-233-M	DMK4IBO	Discovery agent	N.A.	Investigative	[61]
LY320135	DMK3Y5U	Discovery agent	N.A.	Investigative	[62]
Methanandamide	DMZVF6M	Discovery agent	N.A.	Investigative	[63]
Methyl icosylphosphonofluoridate	DM9O5S6	Discovery agent	N.A.	Investigative	[41]
MK-5596	DMLWMZ4	Obesity	5B81	Investigative	[51]
N-(1-adamantyl)-N'-propylsulfamide	DM29QT4	Discovery agent	N.A.	Investigative	[64]
N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide	DM63YJV	Discovery agent	N.A.	Investigative	[65]
N-(2,4-dimethoxyphenethyl)docos-13-enamide	DM3QWZU	Discovery agent	N.A.	Investigative	[31]
N-(2,4-dimethoxyphenethyl)oleamide	DMRQSD2	Discovery agent	N.A.	Investigative	[31]
N-(2-adamantyl)-N'-propylsulfamide	DM6QZPH	Discovery agent	N.A.	Investigative	[64]
N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide	DMU5R2O	Discovery agent	N.A.	Investigative	[48]
N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide	DMAXLVQ	Discovery agent	N.A.	Investigative	[66]
N-(3,3-Diphenyl)propyl-2-phenylacetamide	DMBX0K1	Discovery agent	N.A.	Investigative	[66]
N-(3,5-dimethoxyphenethyl)docos-13-enamide	DM95SJU	Discovery agent	N.A.	Investigative	[31]
N-(3,5-dimethoxyphenethyl)oleamide	DM1C40H	Discovery agent	N.A.	Investigative	[31]
N-(3-Phenyl)propyl-2,2-diphenylacetamide	DM9XH18	Discovery agent	N.A.	Investigative	[66]
N-(3-Phenyl)propyl-2-(4-bromophenylacetamide)	DMSNF7W	Discovery agent	N.A.	Investigative	[66]
N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide	DM7O5WS	Discovery agent	N.A.	Investigative	[65]
N-(4-methoxybenzyl)oleamide	DMHM3LC	Discovery agent	N.A.	Investigative	[31]
N-(4-methoxyphenethyl)oleamide	DM5NOSM	Discovery agent	N.A.	Investigative	[31]
N-(4-methoxyphenyl)oleamide	DMJVPK6	Discovery agent	N.A.	Investigative	[31]
N-(4-morpholinophenyl)docos-13-enamide	DMGRFYV	Discovery agent	N.A.	Investigative	[31]
N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)	DMP7UZB	Discovery agent	N.A.	Investigative	[29]
N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX)	DMDPXUA	Discovery agent	N.A.	Investigative	[29]
N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)	DMSX5DI	Discovery agent	N.A.	Investigative	[29]
N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX)	DM5F27T	Discovery agent	N.A.	Investigative	[29]
N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)	DMO3Y0B	Discovery agent	N.A.	Investigative	[29]
N-(cis-9-cis-12-octadecadienyl)sulfamide	DM1TA5R	Discovery agent	N.A.	Investigative	[64]
N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine	DMF9U2O	Discovery agent	N.A.	Investigative	[67]
N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine	DM49HIO	Discovery agent	N.A.	Investigative	[67]
N-ethyl-5,6-dip-tolylpyrazine-2-carboxamide	DM873WR	Discovery agent	N.A.	Investigative	[68]
N-isopentyl-5,6-dip-tolylpyrazine-2-carboxamide	DMC8L4J	Discovery agent	N.A.	Investigative	[68]
N-isopropyl-5,6-dip-tolylpyrazine-2-carboxamide	DMRPUCA	Discovery agent	N.A.	Investigative	[68]
N-methyl-5,6-dip-tolylpyrazine-2-carboxamide	DMD621E	Discovery agent	N.A.	Investigative	[68]
N-octadecyl-N'-propylsulfamide	DMKTE5V	Discovery agent	N.A.	Investigative	[64]
N-oleoylethanolamide	DMJQ4L7	Discovery agent	N.A.	Investigative	[28]
N-phenyl-5,6-dip-tolylpyrazine-2-carboxamide	DM7XER1	Discovery agent	N.A.	Investigative	[68]
N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX)	DMVY7RX	Discovery agent	N.A.	Investigative	[69]
NAPHTHYRIDINONE	DM0OEGV	Discovery agent	N.A.	Investigative	[29]
O-1812	DMCXMQJ	Discovery agent	N.A.	Investigative	[70]
O-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine	DMWZXH6	Discovery agent	N.A.	Investigative	[67]
Octane-1-sulfonyl fluoride	DMDBI5S	Discovery agent	N.A.	Investigative	[41]
Org27569	DMRU3H0	Discovery agent	N.A.	Investigative	[71]
PARAOXON	DMN4ZKC	Discovery agent	N.A.	Investigative	[41]
PMID26161824C70	DMTO95J	Discovery agent	N.A.	Investigative	[15]
PRAVADOLINE	DM3XRJT	Discovery agent	N.A.	Investigative	[72]
Rac-cis-N-arachidonoylcyclopropanolamide	DMR8L6O	Discovery agent	N.A.	Investigative	[28]
Rac-trans-N-oleoylcyclopropanolamide	DM9DA8O	N. A.	N. A.	Investigative	[28]
SCH-356036	DMOEB8M	Discovery agent	N.A.	Investigative	[73]
SEMIPLENAMIDE A	DMW5SIQ	Discovery agent	N.A.	Investigative	[74]
SEMIPLENAMIDE B	DMHWCFJ	Discovery agent	N.A.	Investigative	[74]
Semiplenamide G	DM4RP0A	Discovery agent	N.A.	Investigative	[74]
VER-156084	DMFZMA2	Neuropathic pain	8E43.0	Investigative	[75]
VER-156085	DMCRHOA	Discovery agent	N.A.	Investigative	[75]
[123I]AM251	DMCJQ0P	Discovery agent	N.A.	Investigative	[76]
[3H]CP55940	DMU7FC5	Discovery agent	N.A.	Investigative	[77]
[3H]HU-243	DM8YUW6	Discovery agent	N.A.	Investigative	[78]
[3H]WIN55212-2	DM0TRAZ	Discovery agent	N.A.	Investigative	[79]
{[(9Z)-octadec-9-en-1-yl]sulfamoyl}amine	DMMB4US	Discovery agent	N.A.	Investigative	[64]

References

• [1] Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
• [2] Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
• [3] Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
• [4] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [5] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [6] Clinical pipeline report, company report or official report of Affimed Therapeutics.
• [7] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [8] Company report (Gwpharm)
• [9] Clinical pipeline report, company report or official report of Bird Rock Bio.
• [10] Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
• [11] ClinicalTrials.gov (NCT04880291) A First-In-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-024 as a Single Dose in Healthy Overweight and Obese Participants and as Multiple Doses in Participants With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
• [12] 2011 Pipeline of 7TM Pharma.
• [13] Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs. 2009 Mar;14(1):43-65.
• [14] 2011 Pipeline of Zydus Cadila Group.
• [15] A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
• [16] Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
• [17] Pfizer. Product Development Pipeline. March 31 2009.
• [18] Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44.
• [19] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [20] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [21] BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury.CNS Drug Rev.2003 Winter;9(4):343-58.
• [22] JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett. 2012 Oct 1;22(19):6173-80.
• [23] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [24] Effects of the novel cannabinoid CB1 receptor antagonist PF 514273 on the acquisition and expression of ethanol conditioned place preference. Alcohol. 2014 Aug;48(5):427-31.
• [25] Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates. Brain Res. 2012 Jan 9;1430:93-100.
• [26] 2011 Pipeline of Jenrin Discovery.
• [27] Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
• [28] Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
• [29] Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
• [30] Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9.
• [31] New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
• [32] Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cann... J Med Chem. 2006 Feb 9;49(3):872-82.
• [33] Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichl... J Med Chem. 2005 Nov 17;48(23):7351-62.
• [34] Synthesis and CB1 cannabinoid receptor affinity of 4-alkoxycarbonyl-1,5-diaryl-1,2,3-triazoles. Bioorg Med Chem Lett. 2009 Feb 1;19(3):891-3.
• [35] Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor. Eur J Med Chem. 2008 Mar;43(3):513-39.
• [36] Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern. Bioorg Med Chem Lett. 2010 May 1;20(9):2770-5.
• [37] 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90.
• [38] Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
• [39] Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4794-8.
• [40] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [41] Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
• [42] New tetrazole-based selective anandamide uptake inhibitors. Bioorg Med Chem Lett. 2008 May 1;18(9):2820-4.
• [43] Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315.
• [44] Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther. 1999 Jun;289(3):1427-33.
• [45] Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500.
• [46] Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem. 1996 Oct 25;39(22):4515-9.
• [47] Heteroadamantyl cannabinoids. J Med Chem. 2010 Aug 12;53(15):5656-66.
• [48] New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10.
• [49] Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004 Apr;309(1):56-63.
• [50] Opioid receptor and NO/cGMP pathway as a mechanism of peripheral antinociceptive action of the cannabinoid receptor agonist anandamide. Life Sci. 2009 Aug 26;85(9-10):351-6.
• [51] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56).
• [52] Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther. 1996 Sep;278(3):989-99.
• [53] Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82.
• [54] Bornyl- and isobornyl-Delta8-tetrahydrocannabinols: a novel class of cannabinergic ligands. J Med Chem. 2008 Oct 23;51(20):6393-9.
• [55] The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004 Apr;113(8):1202-9.
• [56] Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
• [57] Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78.
• [58] 1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor. Bioorg Med Chem. 2010 Nov 15;18(22):7809-15.
• [59] 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
• [60] Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
• [61] Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. Bioorg Med Chem. 2008 Jul 1;16(13):6489-500.
• [62] LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther. 1998 Jan;284(1):291-7.
• [63] Methanandamide attenuates cocaine-induced hyperthermia in rats by a cannabinoid CB1-dopamine D2 receptor mechanism. Brain Res. 2009 Mar 13;1260:7-14.
• [64] Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. Eur J Med Chem. 2009 Dec;44(12):4889-95.
• [65] New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
• [66] Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5.
• [67] Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8.
• [68] Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82.
• [69] Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carbox... J Med Chem. 2010 May 27;53(10):4028-37.
• [70] Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Biochem Biophys Res Commun. 2001 Feb 23;281(2):444-51.
• [71] Indole-2-carboxamides as allosteric modulators of the cannabinoid CB receptor. J Med Chem. 2012 Jun 14;55(11):5627-31.
• [72] Morpholinoalkylindenes as antinociceptive agents: Novel cannabinoid receptor agonists, Bioorg. Med. Chem. Lett. 5(4):381-386 (1995).
• [73] Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1084-9.
• [74] Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. J Nat Prod. 2003 Oct;66(10):1364-8.
• [75] Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4.
• [76] Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci. 1997;61(14):PL 191-7.
• [77] Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem. 1996 Mar 22;271(12):6941-6.
• [78] A novel probe for the cannabinoid receptor. J Med Chem. 1992 May 29;35(11):2065-9.
• [79] Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem. 1998 Jan;70(1):366-73.